Frontotemporal dementia: the state of treatment development
Pharmaceutical Technology
FEBRUARY 20, 2023
The therapy is specifically aimed at treating FTD patients who have mutations in their granulin gene, which encodes for the protein progranulin (PGRN). This protein promotes lysosomal function. In addition to gene therapy, gene silencing, which can be done using ASOs, is also an interesting approach, says Barmada.
Let's personalize your content